DC
BPMC

Deere & Company’s Blueprint Medicines BPMC Stock Holding History

Deere & Company’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-16,023
Closed -$476K – 117
2016
Q3 		$476K Sell
16,023
-5,612
-26% -$139K 0.03% 665
2016
Q2 		$438K Buy
+21,635
New +$393K 0.02% 688

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deere & Company's BPMC Position: Q4 2016 in Review

Deere & Company sold out of Blueprint Medicines (BPMC) in Q4 2016, closing a stake of 16,023 shares — an estimated $476K sold.

Deere & Company first reported a position in BPMC in Q2 2016 and held it in 2 quarters. The position peaked at $476K in Q3 2016. 103 funds tracked by Wall St. Rank hold BPMC as of Q4 2016.

  • Deere & Company reported no remaining Blueprint Medicines position as of Q4 2016 after selling out during the quarter.
  • Deere & Company sold 16,023 Blueprint Medicines shares in Q4 2016, an estimated $476K.
  • Deere & Company first reported a position in Blueprint Medicines in Q2 2016 and held it in 2 quarters.
  • Deere & Company's Blueprint Medicines position peaked at $476K in Q3 2016.
  • 103 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2016.

Based on Deere & Company's 13F filing for Q4 2016, filed 13 Feb 2017.